MARKET

NBY

NBY

NOVABAY PHARMA
AMEX

Real-time Quotes | Nasdaq Last Sale

0.7160
+0.0072
+1.02%
Pre Market: 0.7400 +0.024 +3.35% 08:27 06/21 EDT
OPEN
0.7074
PREV CLOSE
0.7088
HIGH
0.8772
LOW
0.7000
VOLUME
43.23K
TURNOVER
--
52 WEEK HIGH
1.940
52 WEEK LOW
0.5150
MARKET CAP
30.03M
P/E (TTM)
-2.3429
1D
5D
1M
3M
1Y
5Y
BRIEF-NovaBay Pharmaceuticals - Notified By FDA That It Declines To Review Co's EUA Request For Sars-Cov-2 IGG & IGM Antibody Combined Test Kits
reuters.com · 06/11 21:18
Axios Report Shows Covid-19 Positivity Rate Is Lowest Among Those Who Always Wore a Mask
https://www.axios.com/coronavirus-masks-fewer-positive-tests-87a97b0f-6d30-4440-a16f-ef73bb859c2b.html
Benzinga · 06/07 09:27
NYS Department of Education Said Mask Rules Remain in Place
https://abc7ny.com/10751908/?ex_cid=TA_WABC_FB&taid=60bd51b4ba52ee00010b84f1&utm_campaign=trueAnthem:+New+Content+(Feed)&utm_medium=trueAnthem&utm_source=facebook
Benzinga · 06/06 22:54
Kroger Says Fully-Vaccinated Customers, Most Fully-Vaccinated Associates Will No Longer Need To Wear A Facemask In Co.'s Stores As Of May 20
-Reuters
Reuters · 05/19 17:05
BRIEF-Novabay Pharmaceuticals Announces Availability Of I-Chek Illuminated Eye Examination Mirror On Amazon
reuters.com · 05/17 10:56
NovaBay Pharmaceuticals Launches First of Several New Products to Expand Avenova Line
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focusing on expanding its presence in the eye and skin care market, announces the availability of i-Chek Illuminated Eye Examination Mirror on Amazon. i-Chek is a unique portable...
Business Wire · 05/17 10:50
BRIEF-Novabay Pharmaceuticals Files Prospectus Supplement To April 2 Prospectus Entered Into An ATM Offering Agreement For Share Sale Of Up To $4 Mln
reuters.com · 05/14 22:44
Watching Personal Protective Equipment Manufacturers, Alpha Pro Tech, Novabay Following Report From AP The CDC Will Say COVID-19 Vaccinated People Do Not Need To Wear Masks Indoors As Often
-Bloomberg
Bloomberg · 05/13 17:04
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NBY. Analyze the recent business situations of NOVABAY PHARMA through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NBY stock price target is 2.575 with a high estimate of 3.250 and a low estimate of 1.900.
EPS
Institutional Holdings
Institutions: 20
Institutional Holdings: 647.60K
% Owned: 1.54%
Shares Outstanding: 41.94M
TypeInstitutionsShares
Increased
3
383.59K
New
7
174.48K
Decreased
6
97.70K
Sold Out
2
12.42K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.57%
Pharmaceuticals & Medical Research
-0.98%
Key Executives
Non-Executive Chairman/Independent Director
Paul Freiman
President/Chief Executive Officer/Director/IR Contact Officer
Justin Hall
Chief Financial Officer/Treasurer
Andrew Jones
Controller
Wang Xu
Director
Xinzhou Li
Director
Mijia Wu
Independent Director
Swan Sit
Independent Director
Yenyou Zheng
No Data
  • All
  • Financials
  • Insiders
More
About NBY
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.

Webull offers kinds of NovaBay Pharmaceuticals, Inc. stock information, including AMEX:NBY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBY stock methods without spending real money on the virtual paper trading platform.